BRCA1 and ovarian carcinoma: Additionally, we used the Oncomine®BRCA1/2 Panel to detect germline mutations and copy number alterations in randomly-selected patients with breast and/or ovarian cancer, and compared our findings with the sequencing results of the Ion AmpliSeqTM BRCA1/2 Panel.